





Cite this: DOI: 10.1039/d6cs00107f

Catalytic strategies for post-translational modifications regulating protein higher-order structure and properties

Yuki Yamanashi * and Motomu Kanai *

Proteins, the major functional components of living organisms, undergo post-translational modifications (PTMs) that expand their structural and functional diversity. Recent advances in PTM profiling and functional analysis have revealed that many PTMs act as reversible modulators of protein behavior, operating with residue- and domain-level precision to reshape higher-order structures. Both biotic and abiotic catalyses are emerging means of deciphering and controlling PTMs. In this Tutorial Review, we outline how PTMs influence protein architecture across multiple structural scales and survey catalytic strategies that enable their analysis and manipulation.

Received 24th January 2026

DOI: 10.1039/d6cs00107f

rsc.li/chem-soc-rev

Key learning points

- (1) Post-translational modifications (PTMs) as dynamic chemical switches that expand proteomic diversity.
- (2) How PTMs reshape protein higher-order structures.
- (3) Chemical catalysis to decipher or control PTMs.
- (4) How catalysis can help to decipher PTM-related biology.
- (5) How catalysis itself can be a drug *via* PTM regulation.

1. Introduction

Catalysts accelerate chemical reactions without being consumed. In living organisms, enzymes function as highly evolved catalysts, operating with high precision to drive metabolism, reproduction, and countless cellular processes that sustain homeostasis. Because every biological function ultimately arises from networks of molecules and chemical reactions, catalysis constitutes a fundamental layer of control in cellular systems.

Proteins, the primary executors of all molecular phenomena in living organisms, including these catalytic processes, are built from 20 canonical amino acids. The encoded polypeptide sequences (primary structure) form local folds, such as α -helices and β -sheets (secondary structure), which fold into three-dimensional architectures (tertiary structure) and assemble into multi-protein complexes (quaternary structure). These structures define proteins' biological function and activity, which have been optimized through evolution over billions of

years. Proteins continually remodel these higher-order structures, expanding functional diversity.

Post-translational modifications (PTMs), protein modifications performed after their production by the ribosome, further expand the diversity of protein structures beyond the 20 canonical amino acid residues by covalently modifying backbones and side chains.¹ By modulating charge, hydrophobicity, sterics, and hydrogen-bonding capacity, PTMs can rapidly and reversibly reprogram protein behavior. In these regulatory systems, enzymes that install modifications are referred to as “writers,” those that remove them as “erasers,” and proteins that recognize modified residues and translate them into downstream biological responses as “readers.” Representative PTMs are phosphorylation on Ser/Thr/Tyr, *O*-GlcNAcylation on Ser/Thr, *S*-palmitoylation on Cys, acetylation on Lys/N-terminus, methylation on Lys/Arg, and ubiquitination/SUMOylation on Lys (Fig. 1). Irreversible PTMs, including proteolytic cleavage, also play important roles in protein maturation and disease-related protein processing.² This Tutorial Review, however, primarily focuses on reversible PTMs, which are particularly attractive targets for manipulation using biocatalysis or abiotic catalysis.

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan. E-mail: yamanashi@mol.f.u-tokyo.ac.jp, kanai@mol.f.u-tokyo.ac.jp






Fig. 1 Representative post-translational modifications of proteins (ubiquitin: PDB 1UBQ).

Functionally, PTMs operate as chemical switches whose effects propagate from the nanometer to the cellular scale. They stabilize or destabilize local folds to tune the function of a specific protein. They can also remodel protein interfaces to alter interactions with other biomolecules. At larger scales, PTMs help encode the material state of macromolecular assemblies, including biomolecular condensates formed through liquid–liquid phase separation (LLPS).^{3,4} Through these mechanisms, PTMs regulate transcription by RNA polymerase II,⁵ cell-cycle progression,⁶ chromatin dynamics,⁷ and cytoskeletal organization.⁸ Dysregulation of PTM regulators is

directly linked to aging and diseases such as cancer and neurodegeneration.⁹ The types and sites of identified PTMs are continually increasing due to the progress of proteomics,^{10,11} and over 600 types of PTMs have been categorized in UniProt Knowledgebase across all taxa so far.¹²


Despite their importance, the functions of PTMs in living systems remain difficult to dissect because they are often heterogeneous, substoichiometric, and transient. In addition, the functional consequences of PTMs are further complicated by the diversity of the proteome across tissues and cell types, as well as by differences in the expression levels of PTM writers, erasers, and readers. To address these challenges, elucidating the functions of PTMs in cells relies on two complementary strategies: profiling and perturbation. For profiling, mass spectrometry or antibody-based methods (immunoblotting, immunoprecipitation, and imaging) are effective. In particular, mass spectrometry-based proteomics is widely used to identify PTMs that correlate with specific phenotypes, diseases, or drug treatments (Fig. 2a).^{13,14} However, these approaches alone primarily report association rather than causation; temporal resolution can be limited by sample processing; site coverage depends on enrichment, ionization, and antibody specificity. Perturbation of PTMs is required to establish cause and effect. Small-molecule inhibitors of PTM writers/erasers remain the most accessible option and have yielded numerous biological insights (Fig. 2b). Starting from natural products, many studies have developed inhibitors with high selectivity, also motivated by therapeutic need.^{15,16} However, many inhibitors still act on multiple family members, complicating residue-level assignments of PTM roles. The promiscuous nature of writers/erasers is also a fundamental limitation in this method.

By contrast, biological approaches that leverage highly specific genetic manipulation can achieve higher precision (Fig. 2c and d). Site-directed mutagenesis creates PTM “mimics” (e.g. Ser to Ala for non-phosphorylated Ser, Ser to Asp for phosphorylated Ser, Lys to Gln for acetylated Lys), and is mainly used to probe the role of a specific PTM in test tubes.¹⁷ Genetic



Yuki Yamanashi

Yuki Yamanashi graduated from The University of Tokyo in 2020. In the middle of his graduate course, he obtained an assistant professor position at The University of Tokyo in 2023. He received his PhD from The University of Tokyo in 2025. His research focuses on catalytic approaches to control protein function in complex biological systems.



Motomu Kanai

Motomu Kanai graduated from The University of Tokyo in 1989. In the middle of his graduate course, he obtained an assistant professor position at Osaka University in 1992. He received his PhD from Osaka University in 1995. After postdoctoral work at University of Wisconsin, USA, he was appointed as an assistant professor at The University of Tokyo in 1997. He was promoted to a full professor in 2010. His research interests are in the development of molecular catalysis, linking physical and life sciences.






Fig. 2 Methods for profiling (a) or perturbation (b): inhibitor, (c): genetic code expansion, (d): protein *trans*-splicing) of PTMs.

code expansion extends this strategy by installing PTMs or stable analogs in cells (Fig. 2c).¹⁸ Semi-synthetic strategies based on protein *trans*-splicing allow installation of defined PTMs onto cellular proteins with residue-level precision (Fig. 2d).^{19,20} In this method, a synthetic fragment of a split intein bearing the desired PTMs is delivered to cells expressing the target protein fused to the complementary intein fragment, thereby generating the protein with the desired modifications. Although these approaches have advantages in precision and generality, they typically act on exogenously expressed proteins and may not fully reproduce endogenous regulation. The one-shot nature of installation can also limit reversible spatiotemporal control of PTMs. Moreover, the reliance on genetic manipulation complicates therapeutic application. Overall, the lack of broadly applicable, residue- and protein-selective perturbation methods in living systems still constrains causal analysis of how PTMs influence biological phenomena, especially protein higher-order structures, where rapid and regioselective changes can be decisive.^{21,22}

Catalysis offers a direct route to manipulate PTMs. Native or engineered enzymes, induced-proximity strategies, and abiotic chemical catalysts can directly manipulate PTMs with spatiotemporal precision (Fig. 3). These approaches enable cause-and-effect studies of PTMs, thereby bridging mechanistic




Fig. 3 Catalysis for direct manipulation of PTMs. Notably, some methods, particularly those employing abiotic catalysis, enable PTM manipulation without the need for genetic manipulation.

biology and drug discovery. Moreover, this strategy is opening an emerging field in which catalysis itself functions as a therapeutic modality. The idea is to leverage the ability of catalysis that transforms diverse substrates into desired products, potentially in a manner beyond what nature does.

This Tutorial Review first outlines how PTMs shape protein higher-order structures (Section 2) and then surveys catalytic strategies to decipher (Sections 3 and 4) and control (Sections 5 and 6) them. Distinctively, we focus not only on how PTMs can be controlled but also on the consequences of such control for protein structure across scales, presenting an integrated, chemistry-based perspective aimed at an inclusive understanding of these phenomena. Although PTMs span multiple taxa, we focus primarily on human proteins, particularly in disease-related contexts.

2. PTMs and protein higher-order structures

2.1. Overview of PTM regulation

Regulation of most PTMs follows a unified scheme centered on writer and eraser enzymes equipped with catalytic and substrate-recognition motifs.²³ Writers transfer a modification group from a donor molecule to a defined residue on a protein substrate, typically through nucleophilic attack by the target residue, although mechanistic variations exist depending on the PTM chemistry (Fig. 4a). Typical examples include the transfer of the phosphate group from ATP in phosphorylation,




Fig. 4 Unified scheme of PTM regulation by writer enzymes (a) and eraser enzymes (b).



the acetyl group from acetyl-CoA in acetylation, and the methyl group from *S*-adenosyl-L-methionine (SAM) in methylation.

Erasers employ several types of chemistries. The most common mode is hydrolysis, with water acting as the nucleophile (Fig. 4b); this includes many erasers for PTMs that have an electrophilic nature, like phosphatases, deacylases, and deubiquitinases. Cysteine- or serine-based hydrolases capture the PTM to generate a PTM–enzyme covalent intermediate that is subsequently hydrolyzed, whereas metallohydrolases activate water directly. A second mode couples co-substrates: NAD⁺-dependent sirtuin deacetylases consume NAD⁺ to cleave the amide bond of acetylated Lys, yielding nicotinamide and 2'-*O*-acyl-ADP-ribose.²⁴ A third mode is an oxidation-dependent reaction: FAD-dependent demethylases oxidize the ϵ -*N*-methyl group to an iminium that is hydrolyzed to formaldehyde.²⁵

In both directions, active sites preorganize donors and acceptors and tune their reactivity through catalytic residues, metal ions, and cofactors. Exceptions include enzyme-independent PTMs that arise from intrinsic chemical reactivity. Representative cases include oxidative modifications or acylations driven by reactive oxygen species or metabolites such as acyl-CoA thioesters and acyl phosphates. The roles of these nonenzymatic PTMs in disease and aging are being elucidated, and further studies are required.^{26,27}

2.2. Classification of PTM-induced structural effects

Primary effects of PTMs can be classified into two types: intramolecular structural changes and intermolecular interaction changes.²⁸ Intramolecular structural changes include alterations of local folding or covalent topology (*e.g.*, cross-linking) (Fig. 5a). These can alter enzyme catalytic activity or propagate to new intermolecular interactions. Intermolecular structural changes include altered binding to other biomolecules (proteins, nucleic acids, lipids, or small molecules) (Fig. 5b).²⁹ These lead to downstream consequences, including recognition by writer, eraser, or reader proteins,²³ changes in localization,³⁰ altered degradation rates,³¹ and remodeling of larger cellular assemblies such as chromatin,⁷ amyloid,³² cytoskeleton,⁸ and biomolecular condensates.³³ Beltrao, Krogan, and colleagues reported that phosphorylation and

acetylation sites located at protein–protein interfaces are more conserved between *S. cerevisiae* and humans than average PTM sites, indicating that interface-localized PTMs constitute “hot spots” under stronger functional constraint rather than neutral drift. This suggests that interface-localized PTMs are functionally constrained to preserve interaction regulation across evolution.³⁴ Intermolecular interactions of writer or eraser proteins with PTMs further lead to crosstalk among PTMs, introducing or eliminating modifications proximal to one another, thereby forming a complex PTM network exemplified by the chromatin epigenetic code (epigenome) and the tubulin code.^{35,36}

Stability regulation of biomolecules affects biological outcomes. PTMs critically control protein stability and are therefore major therapeutic targets, a theme that recurs throughout this review. Stability regulation by PTMs operates by either stabilization/destabilization of tertiary structures (intramolecular effects)³⁷ or by installing degradation signals, called degrons, exemplified by polyubiquitin chains that target substrates for proteasomal degradation (intermolecular effects).³¹ In the following sections, we illustrate how each class of PTM effects, as classified above, manifests at the molecular and cellular scales.

2.3. PTM-driven intramolecular structural changes

2.3.1. 4E-BP2: phosphorylation-induced folding (disorder to order).

4E-BP2 is an intrinsically disordered protein (IDP) that binds eIF4E *via* a canonical YXXXXLΦ motif (starting at Y54, Φ: a hydrophobic amino acid) to repress cap-dependent translation. Forman-Kay and colleagues showed that phosphorylation of 4E-BP2 at T37/T46 induces folding of residues P18-R62 into a four-stranded β-domain that sequesters the YXXXXLΦ motif, thereby weakening the 4E-BP2–eIF4E interaction (Fig. 6a).³⁸ Fully phosphorylated 4E-BP2 at five positions




Fig. 5 Primary effects of PTMs classified by structural perspective. (a) Intramolecular structural changes. (b) Intermolecular interaction changes.




Fig. 6 The representative examples of PTM-driven intramolecular structural changes. (a) Disorder-to-order change of 4E-BP2 by phosphorylation. Structure of phosphorylated 4E-BP2 (PDB: 2MX4) is illustrated using PyMOL. (b) Order-to-disorder change of p27 by phosphorylation. Structure of complex-binding p27 (PDB: 1JSU) is illustrated using PyMOL.



binds with eIF4E ~4000-fold weaker affinity than the non-phosphorylated protein ($K_d \sim 12 \mu\text{M}$ vs. 3.2 nM). Notably, phospho-mimetic mutations (T37D/T46D or T37E/T46E) did not induce this folding, underscoring the presence of a phosphate-specific hydrogen-bonding network. This highlights the importance of installing authentic PTMs when deciphering their roles. Collectively, these results established PTM-induced folding as a regulatory mechanism in IDPs, showing that PTMs act as stimulus-responsive switches that reversibly modulate protein function by reshaping the conformational ensemble without altering the primary structure.

2.3.2. p27: phosphorylation-induced unfolding (order to disorder). In contrast, the CDK inhibitor p27 exemplifies a PTM-driven protein unfolding that releases an inhibited complex. p27 binds and inhibits cyclin E-CDK2 to prevent premature S-phase entry. Src-family kinases phosphorylate p27 at Y74 and Y88, which reduces steady-state binding to cyclin E-CDK2 and diminishes its inhibitory potency, thereby facilitating CDK2-dependent phosphorylation of p27 at T187 and subsequent degradation.³⁹ Building on this, Senapati's group revealed a two-step reactivation mechanism upon p27 Y88 phosphorylation using molecular dynamics (MD) simulations supported by NMR structural analysis: initial disruption of the p27-CDK2 hybrid β -sheet, followed by ejection of the p27 3_{10} helix from the CDK2 catalytic cleft ("flip-out"), yielding an active, ATP-competent CDK2 (Fig. 6b).⁴⁰ This constitutes a phosphorylation-induced unfolding that loosens p27's grip on CDK2.

2.4. 14-3-3: PTM-driven intermolecular interaction changes

We next survey representative cases in which PTMs rewire intermolecular interactions. Once a PTM is installed or removed, it can alter a protein's binding ability to other proteins, nucleic acids, lipids, or small molecules. This section focuses on how PTMs change recognition by reader modules,²³ stability,³¹ localization,³⁰ and the assembly of larger complexes and condensates.^{7,8,32,33}

Writers and erasers install or remove PTMs, whereas reader proteins decode them. Reader domains typically recognize a local chemical epitope rather than a global protein fold, allowing a small repertoire of modules to interpret PTMs across diverse protein families.

The 14-3-3 protein family exemplifies this logic: 14-3-3 dimers primarily recognize short phosphorylated Ser/Thr motifs rather than global folds, permitting interaction with hundreds of cellular clients across pathways (Fig. 7a).^{41,42} Human cells express seven 14-3-3 isoforms (β , γ , ϵ , ζ , η , σ , τ/θ), which form homo- or heterodimers. Recent thermodynamic profiling revealed isoform-specific hierarchies of phospho-target binding and distinct client selectivity, implying that isoform abundance and pairing stoichiometry help determine the phenotypic output of a given phosphorylation event.⁴³ Functionally, 14-3-3 binding can mask localization or degran motifs, allosterically stabilize specific target conformations, or scaffold multi-protein assemblies. Because a limited set of 14-3-3 dimers can parse many phospho-signals, these adaptors




Fig. 7 The representative example of PTM-driven intermolecular interaction changes. (a) Structure of a 14-3-3 ζ dimer in complex with a phosphorylated C-RAF peptide (PDB: 4FJ3) is illustrated using PyMOL. (b) Stabilization of a specific client-reader pair by a molecular glue DP-005. (c) Structure of a ternary DP-005/p65/14-3-3 complex (PDB: 6NV2) is illustrated using PyMOL.

operate as information hubs in phosphorylation networks, integrating diverse kinase inputs and distributing outputs to cell-cycle control, apoptosis, cytoskeletal remodeling, and metabolism.^{43–45}

Given their hub role, reader proteins are often studied as therapeutic targets. For 14-3-3, its phospho-dependent protein-protein interactions (PPIs) have been defined structurally and mechanistically, and small molecule "molecular glues" have been developed to selectively stabilize reader-client interfaces.⁴⁵ For example, Ottmann and co-workers reported a semisynthetic



fusicocane derivative (DP-005) that preferentially stabilized the 14-3-3/p65 (a subunit of NF- κ B) complex with high cooperativity, yielding client-selective PPI enhancement (Fig. 7b).⁴⁶ Fusicocanes, a class of natural diterpenoid compounds, had long been known to stabilize a subset of 14-3-3 protein interactions,⁴⁷ and subsequent synthetic studies generated derivatives with distinct client- and isoform-selectivity.⁴⁸ However, the rational design principles governing selective molecular glue-mediated PPI stabilization remained largely underexplored.

In this study, DP-005 was identified as a potent stabilizer of the p65/14-3-3 interaction. Fluorescence anisotropy (FA) assays showed that the dissociation constant of the p65/14-3-3 complex decreased from 350 μ M in the absence of compound to 2.8 μ M in the presence of 100 μ M DP-005, corresponding to more than a 100-fold stabilization. Structural and biophysical analyses showed that DP-005 occupied a hydrophobic pocket at the p65/14-3-3 interface, with its sugar moiety engaging the surrounding water shell (Fig. 7c). Because this pocket is largely shaped by the +1 and +2 residues adjacent to the phospho-Ser site (Ile and Pro for p65 S45ph), DP-005 exhibited weaker stabilization for other 14-3-3 client proteins with different +1/+2 residues. Quantitatively, FA measurements showed approximately 6-fold stabilization for CFTR, \sim 2-fold for c-Raf, and little or no stabilization for p53. These trends were further supported by isothermal titration calorimetry (ITC) measurements. Notably, this selectivity did not correlate with the intrinsic affinity of DP-005 for individual client proteins but arose from differences in cooperativity within the corresponding ternary complexes comprising DP-005, 14-3-3, and the phosphorylated client, highlighting how a local PTM can reshape higher-order protein assemblies through reader-mediated interactions.

Given that dysregulation of the NF- κ B pathway is related to cancer proliferation and inflammatory diseases,⁴⁹ selective stabilization of the 14-3-3/p65 interaction can offer a therapeutic strategy, although its translational potential remains to be established.⁵⁰ Subsequent studies on other 14-3-3 clients, including ER α , C-RAF, and CFTR, further support reader proteins as targets for manipulating PTM-dependent interaction networks.⁴⁷

2.5. PTM-driven regulation of larger assemblies

A combination of these intramolecular structural changes or intermolecular interaction changes regulates larger assemblies. In this part, we introduce the representative ones, chromatin, amyloid, cytoskeleton, or biomolecular condensates.

2.5.1. Chromatin: PTMs as regulators of epigenetic state. PTMs on histones and DNA established a framework for epigenetic regulation in which chemical modifications modulate chromatin structure and gene expression independently of the genome (Fig. 8a). In 2000, Strahl and Allis articulated the “histone code” hypothesis, proposing that distinct covalent marks on histones act in combinations to form information units that are written, erased, and read by dedicated enzymes.⁵¹ This hypothesis was rapidly reinforced by mechanistic




Fig. 8 Regulation of chromatin state by PTMs across molecular to mesoscale levels. (a) The histone-code framework. (b) Reader proteins for histone PTMs. Structures of H3 peptide-binding HP1 (PDB: 1GUW) and H4 peptide-binding GCN5 (PDB: 1E6I) are illustrated using PyMOL. (c) Charge modulation by histone PTMs. (d) Regulation of LLPS by histone PTMs.

evidence: in 2001, two independent studies showed that heterochromatin protein 1 (HP1) specifically recognized methylated H3K9 *via* its chromodomain, thereby promoting heterochromatin assembly.^{52,53} A broad repertoire of histone marks—methylation, acetylation, ubiquitination, phosphorylation, ADP-ribosylation, and others—is decoded by modular reader domains.^{54,55} Two archetypes illustrate this principle (Fig. 8b). Chromodomains bind methylated Lys through an aromatic cage constituted by Y21, W42, and F45, compacting or compartmentalizing chromatin depending on context, as in HP1.⁵⁶ Bromodomains are \sim 110-aa modules that recognize acetylated Lys within a hydrophobic pocket bearing a conserved asparagine, thereby linking acetylation to transcriptional activation.⁵⁷ These modules exemplify how chemically conservative recognition mechanisms are reused across diverse proteins to construct modular and combinatorial signaling systems.

Electrostatic interactions also play a crucial role in the chromatin state. For example, acetylation of histones neutralizes the positive charge of Lys on histone tails, weakening electrostatic interactions with DNA and inter-nucleosome interactions (Fig. 8c); H4K16ac in particular disrupts higher-order



chromatin fiber compaction and increases accessibility.^{58–60} Thus, PTMs tune chromatin both through molecular recognition by reader motifs and by physicochemical remodeling of nucleosomes.

In recent years, the histone code has expanded into a biophysical framework (Fig. 8d). HP1-rich heterochromatin domains undergo liquid–liquid phase separation (LLPS), with PTMs such as H3K9 methylation and H3S10 phosphorylation modulating material properties, dynamics, and compartmentalization.^{61,62} Chromatin itself also possesses an intrinsic propensity to phase separate; acetylation and other marks tune nucleosome–nucleosome cohesion and thereby shift condensate behavior.⁶³ Together, these findings emphasize that PTMs couple molecular recognition to emergent physical properties to organize transcription in both space and time.

2.5.2. Amyloid: PTMs in pathological aggregation. Amyloids, protein aggregates formed through cross- β -sheet interactions, are pathological hallmarks of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) (Fig. 9a).^{64,65} Amyloid fibrils assemble through a nucleation-dependent polymerization that involves soluble intermediates, including oligomeric and protofibrillar species, which are widely considered to be major contributors to cytotoxicity.⁶⁶ PTMs critically regulate both the formation and material state of these aggregates by modulating intermolecular contacts, conformational equilibria, and solubility.³²

Phosphorylation of tau is among the best-studied PTMs in amyloid biology.⁶⁷ Hyperphosphorylation is a defining pathological feature. Under near-physiological conditions, phosphorylated tau undergoes LLPS, and the resulting droplets can mature toward amyloid fibrils, positioning LLPS as an intermediate between soluble tau and insoluble aggregate (Fig. 9b).⁶⁸




Fig. 9 Regulation of amyloid formation by PTMs. (a) Formation of amyloid fibrils from monomers. Structure of A β 1–42 fibril (PDB: 2MXU) is illustrated using PyMOL. (b) Hyperphosphorylation-triggered LLPS as an intermediate of tau monomers and fibrils.

Similar PTM-driven regulation is reported for other amyloidogenic proteins. For amyloid- β (A β), phosphorylation at S8 promotes early oligomer formation and accelerates fibrillization, illustrating how a single site-specific modification can bias the aggregation pathway.⁶⁹ For α -synuclein, aggregation is a pathological hallmark of Parkinson's disease, with α -synuclein deposited in Lewy bodies and Lewy neurites. In this context, phosphorylation at S129 is enriched in these lesions and widely used as a marker of pathological α -synuclein, whereas proteolytic cleavage and truncation have also been implicated in modulating aggregation and disease-associated species.^{70,71} For TDP-43, acetylation impairs RNA binding and increases aggregation propensity, yielding insoluble species reminiscent of ALS/FTLD pathology.⁷² More recent work showed that acetylation of TDP-43 at K136 promoted LLPS that evolves toward less fluid, pathological assemblies, an effect counteracted by SIRT1 deacetylation, while RNA binding antagonizes these neurotoxic phase transitions.

Together, these examples illustrate a shared principle: PTMs act as molecular switches that rebalance dynamic condensates and stable amyloid assemblies, linking chemical modification to disease-relevant structural outcomes.

2.6. Short summary

In this section, we grouped PTM effects on protein higher-order structures into two classes: intramolecular structural changes and intermolecular interaction changes. At the molecular scale, PTMs reweight local folding, dynamics, and binding networks to regulate activity, stability, and localization. These effects propagate mesoscale architectures, including chromatin, amyloid, and biomolecular condensates, through multivalency and cooperative assembly. This framework motivates the next sections on catalytic strategies to decipher and control PTM-driven structure and function in living systems.

3. Biocatalysis to decipher effects of PTMs

3.1. Overview

As discussed above, several methodologies have been developed to explore the role of PTMs. In this section, we focus on enzyme-based tools for *in situ* PTM editing to enable cause-and-effect studies of PTMs on higher-order protein structures. Two complementary strategies are considered: (i) leveraging native enzymes as modulators of PTMs in cells and organisms, and (ii) deploying engineered enzymes that expand substrate/site selectivity and provide tighter spatial and temporal control. Together, these biocatalytic approaches connect residue-level editing with structural and systems-level understanding of how PTMs regulate higher-order protein structures.

3.2. Native enzyme-based catalysis

Leveraging native writer or eraser enzymes without protein engineering is the most straightforward way to perturb PTMs. Although the substrate scope of a given enzyme can limit the



range of proteins that can be targeted, native-enzyme perturbations can still yield mechanistic insights when coupled with quantitative proteomic or biophysical analyses that capture the global consequences of PTM introduction or removal. Such combined approaches enable causal links between PTMs and proteome-wide properties, including protein stability, interaction networks, and localization, depending on the analytical context.

3.2.1. Thermal proteome profiling using native *O*-GlcNAc hydrolase. Voadlo and co-workers developed a global method to decipher the role of *O*-GlcNAc modification in protein stability.⁷³ Although PTMs broadly regulate protein stability and degradation, general methods to evaluate their effects on thermal stability had been lacking. *O*-GlcNAc modification is one of such widespread PTMs that regulate protein stability, but its proteome-wide role remained unexplored due to its low chemical stability and low abundance. The authors adopted thermal proteome profiling (TPP), which was originally developed to quantify proteome-wide thermal stability shifts in living cells under diverse perturbations, such as drug treatment⁷⁴ and cell cycle progression,⁷⁵ by measuring soluble protein fractions across temperature gradients using quantitative mass spectrometry (Fig. 10a).⁷⁶ By combining TPP with promiscuous *O*-GlcNAc removal catalyzed by *O*-GlcNAc hydrolase (OGA, CAZy families GH84 protein), they established a system to profile the global impact of *O*-GlcNAc on protein stability as the difference in the melting temperature between samples treated with OGA or mutant OGA lacking enzymatic ability (Fig. 10b). Contrary to the initial expectation that *O*-GlcNAc generally stabilizes proteins, they found that *O*-GlcNAc acted as a bidirectional modulator of thermal stability, causing substantial destabilization for many substrates and modest stabilization for some, depending on proteins. This bidirectional effect, especially destabilization, was attributed not only

to direct modification of target proteins (intramolecular effects) but also to secondary influences on PPIs and complex assembly (intermolecular effects) (Fig. 10c). Overall, this study provides a generalizable framework to probe how PTMs reshape the proteome-wide thermal stability landscape, paving the way for systematic extensions of TPP to other PTMs than *O*-GlcNAc.

3.3. Engineered enzyme-based catalysis

3.3.1. Signal analysis using photoswitchable kinases. Protein engineering enables causal tests of PTM function directly in living systems. Lin and colleagues developed photoswitchable kinases that allow reversible, cofactor-free optical control of phosphorylation signaling in cells.⁷⁷ Because many PTMs operate on rapid timescales, light-programmable regulation provides an ideal strategy to modify PTMs with high spatio-temporal precision. Phosphorylation is particularly attractive, given its central role in signal transduction. Previous optogenetic tools enabled kinase activation⁷⁸ or deactivation,⁷⁹ but these approaches relied largely on light-induced relocalization, rather than a generalizable single-protein design that directly controls catalytic activity anywhere in the cell.

To overcome these limitations, the authors developed pdDronpa, a reversibly dimerizing fluorescent protein that associates under violet (~400 nm) light and dissociates under cyan/green (~500 nm) light irradiation (Fig. 11a). Fusing pdDronpa to kinase scaffolds yielded light-gated kinase variants such as psRaf-1, psMEK1/2, and psCDK5, whose kinase activities are caged or uncaged by light-linked pdDronpa association or dissociation (Fig. 11b). Light irradiation switched kinase activity ON/OFF within minutes, enabling precise programming of phosphorylation ability in cultured cells and




Fig. 10 Thermal proteome profiling (TPP) by the treatment with native *O*-GlcNAc hydrolase. (a) Schematics of TPP. (b) Schematics of TPP combined with native *O*-GlcNAc hydrolase (OGA). (c) Effects of *O*-GlcNAc PTM on thermal stability.




Fig. 11 Signal analysis with photoswitchable kinases. (a) Schematics of photoswitchable fluorescent protein pdDronpa. (b) Schematics of photoswitchable kinases. Structure of MEK1 kinase (PDB: 1S9J) is illustrated using PyMOL. (c) A novel feedback mechanism in Raf-MEK signaling revealed in this study.



therapeutic concept is epigenome editing: installing or erasing histone/DNA marks at chosen genomic loci to reprogram transcription without introducing DNA breaks. This has been achieved by fusing writer/eraser domains to programmable DNA-binding proteins such as zinc finger proteins (ZFs), transcription activator-like effectors (TALEs), and more readily programmable nuclease-null deactivated Cas9 (dCas9).⁹²

Reddy, Gersbach, and colleagues pioneered a dCas9-based approach by fusing the catalytic core of histone acetyltransferase p300 to dCas9, creating a programmable acetyltransferase (Fig. 14a).⁹³ Guide-RNA targeting deposited H3K27ac at promoters and enhancers of targeted genes, and activated transcription with high locus specificity, establishing that chromatin-localized catalytic editing can drive gene expression without DNA cleavage.

Inspired by this dCas9-p300 system, many engineered enzyme systems were developed toward therapeutic purposes.⁹⁴ Notably, Lombardo and co-workers demonstrated durable and efficient *in vivo* gene silencing through “hit-and-run” epigenome editing.⁹⁵ The authors engineered zinc-finger-based epigenetic transcriptional repressors (ETRs) that combine KRAB (recruiter of histone deacetylases and methyltransferases), DNMT3A (DNA methyltransferase), and DNMT3L (co-factor of DNMT3A) domains within one scaffold (Fig. 14b). Delivered as mRNA in lipid nanoparticles to hepatocytes, ETRs induced targeted DNA methylation and repressive histone modifications at the *Pcsk9* locus without DNA breaks, achieving robust silencing and a ~50% reduction of circulating PCSK9 proteins that persisted for nearly one year in mice after a single administration. Importantly, this repression remained detectable even after surgically induced liver regeneration, supporting the high durability of this epigenome manipulation despite

the absence of permanent genome modification and its potentially reversible nature.

Together, these studies established that biocatalytic editing by chromatin-localized, engineered enzymes can precisely manipulate transcriptional states. As the authors proposed, combining such systems with improved delivery technologies (DDS, viral or nanoparticle vectors) could yield gene-specific epigenetic therapies applicable far beyond oncology, including neurological and metabolic diseases.

5.3. PTM regulation with chemical inducers of dimerization

A complementary biological strategy is to chemically rewire PTM enzyme–substrate interactions using bifunctional small molecules. Chemical inducers of dimerization (CIDs) recruit a writer or eraser enzyme into proximity to a target non-native for the enzyme, enabling PTM installation or removal. The prototypical example is proteolysis-targeting chimeras (PROTACs), which recruit an E3 ubiquitin ligase to a protein of interest (POI) to induce ubiquitination and subsequent proteasomal degradation, a concept that revolutionized targeted protein degradation.⁹⁶

Building on this logic, chemical dimerizers have been generalized to other PTMs. In 2020, Choudhary and colleagues developed phosphorylation-inducing chimeric small molecules (PHICS) that recruit kinases, such as AMP-activated protein kinase (AMPK) or protein kinase C (PKC), to non-physiological substrates to promote their phosphorylation (Fig. 15a).⁹⁷ PHICS1 and PHICS2 induced phosphorylation of BRD4 proteins in test tubes by dimerizing BRD4 with AMPK (β 1 isoform) for PHICS1 and PKC for PHICS2, whereas negative-control analogues (iPHICS1/2) lacking BRD4-binding capability were inactive. In addition, PHICS3 targeting Bruton's tyrosine kinase (BTK) induced phosphorylation of overexpressed BTK-Flag *via* AMPK recruitment in living cells. These results demonstrated the feasibility of synthetic dimerizers for controlling phosphorylation.

In 2025, the same group greatly advanced this platform by redesigning both the AMPK-recruiting moiety and the linker architecture to create next-generation PHICS with improved potency.⁹⁸ First-generation PHICS recruited only a specific isoform of AMPK and were effective only in a subset of cell types. Additionally, they required target overexpression or nutrient stress for detectable phosphorylation. To overcome these limitations, the authors employed MK-8722, a pan-AMPK recruiter capable of engaging all major AMPK complexes.⁹⁹ They also optimized linker length and composition to enhance ternary complex formation, resulting in efficient phosphorylation of endogenous BTK proteins under physiological culture conditions without the need for overexpression or nutrient stress. The most effective compound, PHICS 2.5, exhibited strong antiproliferative activity in BTK-dependent lymphoma cell lines (EC_{50} = 3.2 and 5.0 μ M for Raji and Mino cells, respectively), outperforming ibrutinib (EC_{50} > 10 μ M for Raji and Mino cells) and demonstrating the therapeutic potential of proximity-induced phosphorylation (Fig. 15b).




Fig. 14 Engineered enzymes for epigenetic therapy. (a) dCas9-p300 approach for transcriptional activation of specific genes. (b) ZF-ETRs approach for transcriptional silencing of specific genes.






Fig. 15 PTM regulation with chemical inducers of dimerization. (a) Schematics of PHICS. (b) and (c) Next-generation PHICS for regulating dynamic cellular processes.

Notably, they also developed PHICS 3.3 for liprin- α 3 fused an FKBP tag, a presynaptic scaffold protein whose phosphorylation drives LLPS. Proximity-induced phosphorylation of liprin- α 3 using PHICS 3.3 triggered LLPS in living cells, showing that induced kinase recruitment can be used to control membraneless assemblies' formation (Fig. 15c).

Together, the PHICS studies mark a progression from proof-of-principle to programmable control of dynamic cellular processes, underscoring that chemically induced-proximity biocatalysis extends beyond degradation to spatiotemporal rewiring of phosphorylation networks.

5.4. Short summary

In this section, we outlined biological strategies that achieve active control of PTMs by exploiting the high selectivity of enzymes. Biological systems, including engineered enzymes and chemical dimerizers, offer programmable and reversible modulation of PTMs through precise molecular recognition. With these platforms in hand, their therapeutic potential is increasingly being explored as novel drug modalities that access protein higher-order structures and functions *via* PTM control. Advancing translational aspects, including ADMET properties, together with further improvements in reactivity and selectivity, represents a critical next step toward practical applications.

6. Abiotic catalysis to control PTMs

6.1. Overview

Abiotic catalysis for PTM control, as introduced in Section 4, can also be used for therapeutic purposes. In principle, this strategy is not constrained by naturally evolved enzymatic reaction and can therefore include virtually any chemical transformation, offering a broader reaction space than enzyme-dependent biocatalysis alone. In addition, abiotic approaches can employ synthetic small-molecule catalysts, which may exhibit superior drug-like properties.

Our group is pursuing this direction by postulating the concept of “catalysis medicine,” in which abiotic catalysts manipulate post-translational modifications (PTMs) in living systems toward therapeutic applications.^{100,101} This approach enables a purely chemical way to probe and reprogram biological architectures without genetic manipulation.

6.2. Abiotic catalysis for epigenetic therapy

A recent advance demonstrated the potential of this strategy in epigenetic therapy. We developed an abiotic nucleophilic catalyst that promotes acetylation of histone proteins using a stable acetyl donor with high selectivity for H2BK120.^{102–104} This selective reaction is achieved through ligand-directed chemistry⁸⁸ combined with our original catalyst core for lysine acylation,^{89,102,105} as discussed in Section 4. The LANA peptide serves as a nucleosome-binding ligand, positioning the catalytic core to acetylate the proximal lysine under physiological conditions (Fig. 16a). The optimized catalyst, BAHA-LANA-PEG-CPP44,






Fig. 16 Abiotic catalysis for epigenetic therapy. (a) Schematics of abiotic catalyst for acetylation of lysine on histones in living cells. (b) BAHA-LANA-PEG-CPP44 catalyst system for manipulation of cancer epigenome and transcription.

which had selective cell-membrane permeability toward leukemia cells, induced acetylation of endogenous H2BK120 across multiple leukemia cell lines. Time-resolved analyses revealed that this site-specific acetylation displaced the negative transcription elongation factor (NELF) complex from chromatin, thereby activating some genes by releasing RNA polymerase II (Pol II) from NELF-mediated suppression (Fig. 16b). We also observed that this epigenome reprogramming suppressed leukemia cell proliferation and tumorigenicity *in vivo*, establishing a causal connection

between a chemically installed PTM, local chromatin remodelling, and transcriptional control. The regioselectivity of the catalytic histone acylation was recently extended from H2BK120 to H2BK108 and H2BK43, promising further utility of this approach in furnishing other biological activities.¹⁰⁶

6.3. Abiotic catalysis for amyloid photooxygenation

Building on the concept of “catalysis medicine,” our group has also pursued the chemical regulation of protein higher-order assemblies, such as amyloids. Traditional therapeutic strategies of amyloidosis have focused on inhibiting amyloid formation or promoting clearance by biological means, such as anti-amyloid antibody drugs.¹⁰⁷ In contrast, a purely chemical approach using small molecules to directly remodel or degrade amyloid assemblies remained largely unexplored, despite its advantages in availability and cost for therapeutic applications.

To address this challenge, we developed a series of abiotic catalysts capable of selectively oxygenating His or Met on amyloid fibrils under physiological conditions and light irradiation.¹⁰⁸ As a representative example, leuco ethyl violet (LEV) is a highly active, small-molecule, blood-brain barrier (BBB)-permeable catalyst enabling amyloid oxygenation in Alzheimer model mice (Fig. 17a).¹⁰⁹ LEV is a prodrug form of the active catalyst, ethyl violet (EV), which is produced from LEV through an autocatalytic process. The catalytic photooxygenation of amyloids reduced their cytotoxicity and seeding ability, enhanced microglial uptake and degradation of modified




Fig. 17 Abiotic catalysis for amyloid oxygenation. (a) Amyloid photooxygenation by abiotic catalyst. (b) Schematics of amyloid-selective photooxygenation *via* singlet oxygen generation.



species, thereby demonstrating that the chemical protein oxidation event can modulate complex proteostasis and biological clearance pathways.^{110,111} These catalysts operate through a photochemically driven mechanism in which the microenvironment of amyloid fibrils stabilizes the excited singlet state of the catalyst ($^1\text{cat}^*$), preventing rapid thermal relaxation (Fig. 17b). After intersystem crossing (ISC), the generated long-lived triplet state ($^3\text{cat}^*$) activates ground-state triplet oxygen ($^3\text{O}_2$) to singlet oxygen ($^1\text{O}_2$). The resulting locally generated singlet oxygen oxidizes the His¹¹² and Met side chains of A β amyloid. The amyloid-selective photooxygenation has recently been extended to intracellular amyloid, α -synuclein, despite the reducing cellular environment.¹¹³ The controlled local generation of $^1\text{O}_2$ in the vicinity of amyloid, driven by the catalyst's amyloid-sensing function, is the key to this phenomenon. Furthermore, we identified therapeutic effects of the catalytic photooxygenation within an animal model of transthyretin amyloidosis.¹¹⁴ Therefore, the small-molecule catalysis may be useful for therapeutics to treat various amyloidoses.

6.4. Short summary

In this section, we outlined abiotic strategies that manipulate histone epigenetics and induce amyloid degradation. Abiotic catalysts expand chemical possibilities by introducing reaction pathways beyond those available in nature, enabling direct manipulation of protein structures and assemblies. Furthermore, such catalysis studies will lead to a new modality for treating various diseases.

7. Conclusion and perspectives

PTMs constitute a universal mechanism that couples the chemical state of proteins to their structural and functional organization. Through site-selective and reversible chemical reactions, PTMs dynamically reshape protein conformation, stability, intermolecular interactions, and ultimately the architecture of higher-order assemblies such as chromatin, amyloids, and phase-separated condensates. As accumulating evidence reveals, these structural transitions are not secondary byproducts but represent a physical basis through which biological systems process, transfer, and store information. Catalysis-based PTM control provides a powerful framework to decipher and control these processes with molecular precision. Enzyme-based biological catalysis and abiotic catalysis now enable direct interrogation of PTMs in living systems, bridging molecular chemistry, cellular biology, and medicine.

Despite such progress, precise catalytic modulation of PTMs on dilute targets within crowded, heterogeneous cellular environments remains in its early stages. Although protein engineering has delivered tools with high spatial and temporal control, realizing analogous capabilities with small-molecule catalysts that operate *in vivo* remains a central challenge, particularly for therapeutic applications. Key hurdles include selective access to individual residues, resistance to redox and pH fluctuations,

stability in cells and animals, and rigorous, structure-resolved evaluation of downstream biological consequences for distinguishing direct effects of catalytic PTM modulation from indirect cellular responses. In addition, because PTM-dependent structural transitions and their biological outcomes are often tissue- or cell-type specific, it is essential to study these processes in physiologically relevant systems, particularly in contexts such as neurodegenerative diseases where protein aggregation occurs in post-mitotic neurons. Advances in chemical synthesis, reaction design, and analytical platforms will be required to address these limitations. Mass-spectrometry-based methods and structural proteomics must evolve further to capture transient and substoichiometric PTM states, along with their conformational consequences. Equally important will be progress in molecular delivery technologies, including cell-permeable motifs and nanocarriers that can transport catalytic systems to defined intracellular or *in vivo* locations.

In summary, the convergence of catalysis, PTM chemistry, and structural biology is redefining how protein architectures can be understood and manipulated. By converting chemical reactivity into a mechanism capable of writing, erasing, and reorganizing protein structures, catalysis is poised to become a central principle for both fundamental biochemical analysis and therapeutic intervention. Continued development of catalytic strategies for PTM control will deepen our understanding of protein structural dynamics and may inaugurate a broader paradigm of catalysis-driven medicine.

Conflicts of interest

There are no conflicts to declare.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Acknowledgements

This work was supported by JPMJCR2572 (JST-CREST, MK), JP23H05466 (JSPS KAKENHI, MK), and JPMJAX242K (JST-ACT-X, YY).

References

- 1 S. Prabakaran, G. Lippens, H. Steen and J. Gunawardena, *Wiley Interdiscip. Rev.: Syst. Biol. Med.*, 2012, **4**, 565–583.
- 2 T. Klein, U. Eckhard, A. Dufour, N. Solis and C. M. Overall, *Chem. Rev.*, 2018, **118**, 1137–1168.
- 3 Y.-Y. Luo, J.-J. Wu and Y.-M. Li, *Chem. Commun.*, 2021, **57**, 13275–13287.
- 4 F. Chu, S. Sharma, S. D. Ginsberg and G. Chiosis, *Trends Biochem. Sci.*, 2025, **50**(10), 892–905.



- 5 B. M. LeBlanc, R. Y. Moreno, E. E. Escobar, M. K. V. Ramani, J. S. Brodbelt and Y. Zhang, *RSC Chem. Biol.*, 2021, **2**, 1084–1095.
- 6 S. A. G. Cuijpers and A. C. O. Vertegaal, *Trends Biochem. Sci.*, 2018, **43**, 251–268.
- 7 C. M. D. de Fenffe, J. Govers and F. Mattioli, *Biochemistry*, 2025, **64**, 2138–2153.
- 8 B. MacTaggart and A. Kashina, *Cytoskeleton*, 2021, **78**, 142–173.
- 9 Q. Zhong, X. Xiao, Y. Qiu, Z. Xu, C. Chen, B. Chong, X. Zhao, S. Hai, S. Li, Z. An and L. Dai, *MedComm*, 2023, **4**, e261.
- 10 M. den Ridder, P. Daran-Lapujade and M. Pabst, *FEMS Yeast Res.*, 2019, **20**, foz088.
- 11 Y. Zhang, B. R. Fonslow, B. Shan, M.-C. Baek and J. R. Yates, *Chem. Rev.*, 2013, **113**, 2343–2394.
- 12 https://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/docs/ptmlist.txt.
- 13 S. Doll and A. L. Burlingame, *ACS Chem. Biol.*, 2015, **10**, 63–71.
- 14 L. Zhai, K. Chen, B. Hao and M. Tan, *Acta Pharmacol. Sin.*, 2022, **43**, 3112–3129.
- 15 M. K. Tarrant and P. A. Cole, *Annu. Rev. Biochem.*, 2009, **78**, 797–825.
- 16 J. White, F. A. Derheimer, K. Jensen-Pergakes, S. O'Connell, S. Sharma, N. Spiegel and T. A. Paul, *Trends Pharmacol. Sci.*, 2024, **45**, 243–254.
- 17 K. W. Barber and J. Rinehart, *Nat. Chem. Biol.*, 2018, **14**, 188–192.
- 18 T. Peng, T. Das, K. Ding and H. C. Hang, *Protein Sci.*, 2023, **32**, e4618.
- 19 Y. David, M. Vila-Perelló, S. Verma and T. W. Muir, *Nat. Chem.*, 2015, **7**, 394–402.
- 20 A. J. Burton, M. Haugbro, E. Parisi and T. W. Muir, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 12041–12049.
- 21 J. Roca-Martinez, T. Lazar, J. Gavalda-Garcia, D. Bickel, R. Pancsa, B. Dixit, K. Tzavella, P. Ramasamy, M. Sanchez-Fornaris, I. Grau and W. F. Vranken, *Front. Mol. Biosci.*, 2022, **9**, 959956.
- 22 M. C. Marrero, V. H. Mello, P. Sartori and P. Beltrao, *Nat. Commun.*, 2025, **16**, 9407.
- 23 M. J. Suskiewicz, *BioEssays*, 2024, **46**, e2300178.
- 24 M. D. Jackson and J. M. Denu, *J. Biol. Chem.*, 2002, **277**, 18535–18544.
- 25 Y. Shi, F. Lan, C. Matson, P. Mulligan, J. R. Whetstone, P. A. Cole, R. A. Casero and Y. Shi, *Cell*, 2004, **119**, 941–953.
- 26 I. Maksimovic and Y. David, *Trends Biochem. Sci.*, 2021, **46**, 718–730.
- 27 T. Baldensperger, M. Preissler and C. F. W. Becker, *RSC Chem. Biol.*, 2024, **6**, 129–149.
- 28 P. Beltrao, P. Bork, N. J. Krogan and V. van Noort, *Mol. Syst. Biol.*, 2013, **9**, MSB134521.
- 29 X. Hong, N. Li, J. Lv, Y. Zhang, J. Li, J. Zhang and H.-F. Chen, *Bioinformatics*, 2022, **39**, btac823.
- 30 W. Li, J. Shen, A. Zhuang, R. Wang, Q. Li, A. Rabata, Y. Zhang and D. Cao, *Cell. Mol. Biol. Lett.*, 2025, **30**, 98.
- 31 J. M. Lee, H. M. Hammarén, M. M. Savitski and S. H. Baek, *Nat. Commun.*, 2023, **14**, 201.
- 32 S. P. Moon, A. T. Balana and M. R. Pratt, *Curr. Opin. Chem. Biol.*, 2021, **64**, 76–89.
- 33 J. Li, M. Zhang, W. Ma, B. Yang, H. Lu, F. Zhou and L. Zhang, *Mol. Biomed.*, 2022, **3**, 13.
- 34 P. Beltrao, V. Albanèse, L. R. Kenner, D. L. Swaney, A. Burlingame, J. Villén, W. A. Lim, J. S. Fraser, J. Frydman and N. J. Krogan, *Cell*, 2012, **150**, 413–425.
- 35 M. Leutert, S. W. Entwisle and J. Villén, *Mol. Cell. Proteomics*, 2021, **20**, 100129.
- 36 C. Janke and M. M. Magiera, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 307–326.
- 37 P. Craveur, T. J. Narwani, J. Rebehmed and A. G. de Brevern, *Amino Acids*, 2019, **51**, 1065–1079.
- 38 A. Bah, R. M. Vernon, Z. Siddiqui, M. Krzeminski, R. Muhandiram, C. Zhao, N. Sonenberg, L. E. Kay and J. D. Forman-Kay, *Nature*, 2015, **519**, 106–109.
- 39 I. Chu, J. Sun, A. Arnaout, H. Kahn, W. Hanna, S. Narod, P. Sun, C.-K. Tan, L. Hengst and J. Slingerland, *Cell*, 2007, **128**, 281–294.
- 40 S. L. Rath and S. Senapati, *Sci. Rep.*, 2016, **6**, 26450.
- 41 C. Johnson, S. Crowther, M. J. Stafford, D. G. Campbell, R. Toth and C. MacKintosh, *Biochem. J.*, 2010, **427**, 69–78.
- 42 M. Molzan and C. Ottmann, *J. Mol. Biol.*, 2012, **423**, 486–495.
- 43 G. Gogl, K. V. Tugaeva, P. Eberling, C. Kostmann, G. Trave and N. N. Sluchanko, *Nat. Commun.*, 2021, **12**, 1677.
- 44 K. Pennington, T. Chan, M. Torres and J. Andersen, *Oncogene*, 2018, **37**, 5587–5604.
- 45 B. A. Somsen, P. J. Cossar, M. R. Arkin, L. Brunsveld and C. Ottmann, *ChemBioChem*, 2024, **25**, e202400214.
- 46 M. Wolter, P. de Vink, J. F. Neves, S. Srdanović, Y. Higuchi, N. Kato, A. Wilson, I. Landrieu, L. Brunsveld and C. Ottmann, *J. Am. Chem. Soc.*, 2020, **142**, 11772–11783.
- 47 Y. Tian, L. Li, L. Wu, Q. Xu, Y. Li, H. Pan, T. Bing, X. Bai, A. V. Finko, Z. Li and J. Bian, *J. Med. Chem.*, 2025, **68**, 2124–2146.
- 48 Y. Liu and R. Hong, *Cell Rep. Phys. Sci.*, 2024, **5**, 102141.
- 49 Q. Guo, Y. Jin, X. Chen, X. Ye, X. Shen, M. Lin, C. Zeng, T. Zhou and J. Zhang, *Signal Transduction Targeted Ther.*, 2024, **9**, 53.
- 50 Y. Pan, S. Gangwar, M. Abbas and K. Raza, *Sci. Rep.*, 2025, **15**, 11708.
- 51 B. D. Strahl and C. D. Allis, *Nature*, 2000, **403**, 41–45.
- 52 A. J. Bannister, P. Zegerman, J. F. Partridge, E. A. Miska, J. O. Thomas, R. C. Allshire and T. Kouzarides, *Nature*, 2001, **410**, 120–124.
- 53 M. Lachner, D. O'Carroll, S. Rea, K. Mechtler and T. Jenuwein, *Nature*, 2001, **410**, 116–120.
- 54 C. A. Musselman, M.-E. Lalonde, J. Côté and T. G. Kutateladze, *Nat. Struct. Mol. Biol.*, 2012, **19**, 1218–1227.
- 55 J. Jung and M. S. Werner, *Trends Genet.*, 2026, **42**(2), 126–136.
- 56 P. R. Nielsen, D. Nietlispach, H. R. Mott, J. Callaghan, A. Bannister, T. Kouzarides, A. G. Murzin, N. V. Murzina and E. D. Laue, *Nature*, 2002, **416**, 103–107.



- 57 D. J. Owen, P. Ornaghi, J. Yang, N. Lowe, P. R. Evans, P. Ballario, D. Neuhaus, P. Filetici and A. A. Travers, *EMBO J.*, 2000, **19**, 6141–6149.
- 58 M. Shogren-Knaak, H. Ishii, J.-M. Sun, M. J. Pazin, J. R. Davie and C. L. Peterson, *Science*, 2006, **311**, 844–847.
- 59 R. Collepardo-Guevara, G. Portella, M. Vendruscolo, D. Frenkel, T. Schlick and M. Orozco, *J. Am. Chem. Soc.*, 2015, **137**, 10205–10215.
- 60 M. Shvedunova and A. Akhtar, *Nat. Rev. Mol. Cell Biol.*, 2022, **23**, 329–349.
- 61 A. G. Larson, D. Elnatan, M. M. Keenen, M. J. Trnka, J. B. Johnston, A. L. Burlingame, D. A. Agard, S. Redding and G. J. Narlikar, *Nature*, 2017, **547**, 236–240.
- 62 A. R. Strom, A. V. Emelyanov, M. Mir, D. V. Fyodorov, X. Darzacq and G. H. Karpen, *Nature*, 2017, **547**, 241–245.
- 63 B. A. Gibson, L. K. Doolittle, M. W. G. Schneider, L. E. Jensen, N. Gamarra, L. Henry, D. W. Gerlich, S. Redding and M. K. Rosen, *Cell*, 2019, **179**, 470–484.e21.
- 64 D. Willbold, B. Strodel, G. F. Schröder, W. Hoyer and H. Heise, *Chem. Rev.*, 2021, **121**, 8285–8307.
- 65 S. H. W. Scheres, B. Ryskeldi-Falcon and M. Goedert, *Nature*, 2023, **621**, 701–710.
- 66 M. S. Hipp, P. Kasturi and F. U. Hartl, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 421–435.
- 67 S. Wegmann, J. Biernat and E. Mandelkow, *Curr. Opin. Neurobiol.*, 2021, **69**, 131–138.
- 68 S. Wegmann, B. Eftekhazadeh, K. Tepper, K. M. Zoltowska, R. E. Bennett, S. Dujardin, P. R. Laskowski, D. MacKenzie, T. Kamath, C. Commins, C. Vanderburg, A. D. Roe, Z. Fan, A. M. Molliex, A. Hernandez-Vega, D. Muller, A. A. Hyman, E. Mandelkow, J. P. Taylor and B. T. Hyman, *EMBO J.*, 2018, **37**, EMBJ201798049.
- 69 S. Kumar, N. Rezaei-Ghaleh, D. Terwel, D. R. Thal, M. Richard, M. Hoch, J. M. M. Donald, U. Wüllner, K. Glebov, M. T. Heneka, D. M. Walsh, M. Zweckstetter and J. Walter, *EMBO J.*, 2011, **30**, 2255–2265.
- 70 H. Park, T.-I. Kam, V. L. Dawson and T. M. Dawson, *Nat. Rev. Neurol.*, 2025, **21**, 32–47.
- 71 A. Bluhm, S. Schrepel, S. von Hörsten, A. Schulze and S. Roßner, *Int. J. Mol. Sci.*, 2021, **22**, 5450.
- 72 T. J. Cohen, A. W. Hwang, C. R. Restrepo, C.-X. Yuan, J. Q. Trojanowski and V. M. Y. Lee, *Nat. Commun.*, 2015, **6**, 5845.
- 73 D. T. King, J. E. Serrano-Negrón, Y. Zhu, C. L. Moore, M. D. Shoulders, L. J. Foster and D. J. Vocadlo, *J. Am. Chem. Soc.*, 2022, **144**, 3833–3842.
- 74 M. M. Savitski, F. B. M. Reinhard, H. Franken, T. Werner, M. F. Savitski, D. Eberhard, D. M. Molina, R. Jafari, R. B. Dovega, S. Klaeger, B. Kuster, P. Nordlund, M. Bantscheff and G. Drewes, *Science*, 2014, **346**, 1255784.
- 75 I. Becher, A. Andrés-Pons, N. Romanov, F. Stein, M. Schramm, F. Baudin, D. Helm, N. Kurzawa, A. Mateus, M.-T. Mackmull, A. Typas, C. W. Müller, P. Bork, M. Beck and M. M. Savitski, *Cell*, 2018, **173**, 1495–1507.e18.
- 76 A. Mateus, N. Kurzawa, I. Becher, S. Sridharan, D. Helm, F. Stein, A. Typas and M. M. Savitski, *Mol. Syst. Biol.*, 2020, **16**, MSB199232.
- 77 X. X. Zhou, L. Z. Fan, P. Li, K. Shen and M. Z. Lin, *Science*, 2017, **355**, 836–842.
- 78 J. E. Toettcher, O. D. Weiner and W. A. Lim, *Cell*, 2013, **155**, 1422–1434.
- 79 O. Dagliyan, M. Tarnawski, P.-H. Chu, D. Shirvanyants, I. Schlichting, N. V. Dokholyan and K. M. Hahn, *Science*, 2016, **354**, 1441–1444.
- 80 N. V. Kukushkin, T. Tabassum and T. J. Carew, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**, e2210478119.
- 81 K. Islam, *Cell Chem. Biol.*, 2018, **25**, 1171–1184.
- 82 C. A. Ocasio, M. P. Baggelaar, J. Siphthorp, A. L. de la Lastra, M. Tavares, J. Volarić, C. Souly, E. M. Storck, J. W. Houghton, S. A. Palma-Duran, J. I. MacRae, G. Tomić, L. Carr, J. Downward, U. S. Eggert and E. W. Tate, *Nat. Biotechnol.*, 2024, **42**, 1548–1558.
- 83 M. S. Rana, P. Kumar, C.-J. Lee, R. Verardi, K. R. Rajashankar and A. Banerjee, *Science*, 2018, **359**(6372), eaao6326.
- 84 Y. Mo, Y. Han, Y. Chen, C. Fu, Q. Li, Z. Liu, M. Xiao and B. Xu, *Mol. Cancer*, 2024, **23**, 274.
- 85 H. Zhang, Y. Sun, Z. Wang, X. Huang, L. Tang, K. Jiang and X. Jin, *Nat. Commun.*, 2024, **15**, 4642.
- 86 E. H. Garst, H. Lee, T. Das, S. Bhattacharya, A. Percher, R. Wiewiora, I. P. Witte, Y. Li, T. Peng, W. Im and H. C. Hang, *ACS Chem. Biol.*, 2021, **16**, 844–856.
- 87 Z. Liu, S. Xi, L. A. McGregor, K. Yamatsugu, S. A. Kawashima, J. T. Sczepanski and M. Kanai, *Angew. Chem., Int. Ed.*, 2025, **64**, e202500162.
- 88 S. Sakamoto and I. Hamachi, *Isr. J. Chem.*, 2023, **63**, e202200077.
- 89 C. Adamson, H. Kajino, S. A. Kawashima, K. Yamatsugu and M. Kanai, *J. Am. Chem. Soc.*, 2021, **143**, 14976–14980.
- 90 P. B. Dervan, *Bioorg. Med. Chem.*, 2001, **9**, 2215–2235.
- 91 D. R. Banerjee, C. E. Deckard, M. B. Elinski, M. L. Buzbee, W. W. Wang, J. D. Batteas and J. T. Sczepanski, *J. Am. Chem. Soc.*, 2018, **140**, 8260–8267.
- 92 M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna and E. Charpentier, *Science*, 2012, **337**, 816–821.
- 93 I. B. Hilton, A. M. D'Ippolito, C. M. Vockley, P. I. Thakore, G. E. Crawford, T. E. Reddy and C. A. Gersbach, *Nat. Biotechnol.*, 2015, **33**, 510–517.
- 94 L. Yuan, Y. Xiong, Y. Zhang, S. Gu and Y. Lei, *Mol. Ther.*, 2026, **34**, 46–67.
- 95 M. A. Cappelluti, V. M. Poeta, S. Valsoni, P. Quarato, S. Merlin, I. Merelli and A. Lombardo, *Nature*, 2024, **627**, 416–423.
- 96 M. Békés, D. R. Langley and C. M. Crews, *Nat. Rev. Drug Discovery*, 2022, **21**, 181–200.
- 97 S. U. Siriwardena, D. N. P. M. Godage, V. M. Shoba, S. Lai, M. Shi, P. Wu, S. K. Chaudhary, S. L. Schreiber and A. Choudhary, *J. Am. Chem. Soc.*, 2020, **142**, 14052–14057.
- 98 R. Pergu, V. Srekanth, P. Kokkonda, S. Lai, P. K. Tiwari, S. Singh, J. Kawai, S. Singha, W. Tian, V. Thimaradka, S. Siriwongsup, K. Tran and A. Choudhary, *J. Am. Chem. Soc.*, 2025, **147**, 25316–25324.
- 99 R. W. Myers, H.-P. Guan, J. Ehrhart, A. Petrov, S. Prahalada, E. Tozzo, X. Yang, M. M. Kurtz, M. Trujillo, D. G. Trotter,



- D. Feng, S. Xu, G. Eiermann, M. A. Holahan, D. Rubins, S. Conarello, X. Niu, S. C. Souza, C. Miller, J. Liu, K. Lu, W. Feng, Y. Li, R. E. Painter, J. A. Milligan, H. He, F. Liu, A. Ogawa, D. Wisniewski, R. J. Rohm, L. Wang, M. Bunzel, Y. Qian, W. Zhu, H. Wang, B. Bennet, L. L. Scheuch, G. E. Fernandez, C. Li, M. Klimas, G. Zhou, M. van Heek, T. Biftu, A. Weber, D. E. Kelley, N. Thornberry, M. D. Erion, D. M. Kemp and I. K. Sebbat, *Science*, 2017, **357**, 507–511.
- 100 M. Kanai and Y. Takeuchi, *Tetrahedron*, 2023, **131**, 133227.
- 101 M. Habazaki and M. Kanai, *ACS Catal.*, 2025, **15**, 21137–21151.
- 102 Y. Amamoto, Y. Aoi, N. Nagashima, H. Suto, D. Yoshidome, Y. Arimura, A. Osakabe, D. Kato, H. Kurumizaka, S. A. Kawashima, K. Yamatsugu and M. Kanai, *J. Am. Chem. Soc.*, 2017, **139**, 7568–7576.
- 103 Y. Fujiwara, Y. Yamanashi, A. Fujimura, Y. Sato, T. Kujirai, H. Kurumizaka, H. Kimura, K. Yamatsugu, S. A. Kawashima and M. Kanai, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2019554118.
- 104 Y. Yamanashi, S. Takamaru, A. Okabe, S. Kaito, Y. Azumaya, Y. R. Kamimura, K. Yamatsugu, T. Kujirai, H. Kurumizaka, A. Iwama, A. Kaneda, S. A. Kawashima and M. Kanai, *Nat. Commun.*, 2025, **16**, 887.
- 105 W. Hamajima, A. Fujimura, Y. Fujiwara, K. Yamatsugu, S. A. Kawashima and M. Kanai, *ACS Chem. Biol.*, 2019, **14**, 1102–1109.
- 106 T. Nozaki, M. Onoda, M. Habazaki, Y. Takeuchi, H. Ishida, Y. Sato, T. Kujirai, K. Hanada, K. Yamatsugu, H. Kurumizaka, H. Kimura, H. Kono, S. A. Kawashima and M. Kanai, *J. Am. Chem. Soc.*, 2025, **147**, 13732–13743.
- 107 E. Francis, S. Paylor, C. Van, B. Mathews, M. J. Sobhanian, D. Z. Mansour, G. Hennawi and N. J. Brandt, *Expert Rev. Clin. Pharmacol.*, 2025, 1–16, ahead-of-print.
- 108 Y. Sohma, T. Sawazaki and M. Kanai, *Org. Biomol. Chem.*, 2021, **19**, 10017–10029.
- 109 M. Furuta, S. Arii, H. Umeda, R. Matsukawa, K. Shizu, H. Kaji, S. A. Kawashima, Y. Hori, T. Tomita, Y. Sohma, H. Mitsunuma and M. Kanai, *Adv. Sci.*, 2024, **11**, 2401346.
- 110 N. Nagashima, S. Ozawa, M. Furuta, M. Oi, Y. Hori, T. Tomita, Y. Sohma and M. Kanai, *Sci. Adv.*, 2021, **7**, eabc9750.
- 111 S. Ozawa, Y. Hori, Y. Shimizu, A. Taniguchi, T. Suzuki, W. Wang, Y. W. Chiu, R. Koike, S. Yokoshima, T. Fukuyama, S. Takatori, Y. Sohma, M. Kanai and T. Tomita, *Brain*, 2021, **144**, 1884–1897.
- 112 R. Matsukawa, M. Yamane and M. Kanai, *Chem. Rec.*, 2023, **23**, e202300198.
- 113 A. Iwai, Y. Hwang, H. Umeda, T. Sawazaki, I. Tomizawa, M. Ono, M. Higuchi, Y. Sohma, Y. Hori, T. Tomita, H. Mitsunuma and M. Kanai, *ChemistryEurope*, 2025, **4**(1), e202500192.
- 114 M. Yamane, H. Umeda, M. Toyobe, A. Iwai, K. Ishihara, G. Kudo, H. Mitsunuma, Y. Hori, T. Tomita, M. Mizuguchi, M. Okada, M. Ueda, Y. Ando, S. A. Kawashima, Y. Sohma, H. Kaji, T. Hirokawa, K. Yamanaka and M. Kanai, *J. Am. Chem. Soc.*, 2025, **147**, 28860–28874.

